Hangzhou Tigermed Consulting Co., Ltd (HKG: 3347)

Market Cap	52.63B
Revenue (ttm)	7.53B
Net Income (ttm)	1.06B
Shares Out	n/a
EPS (ttm)	1.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Jun 7, 2024

Volume	1,951,100
Open	34.70
Previous Close	34.00
Day's Range	31.95 - 34.70
52-Week Range	22.10 - 58.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About Hangzhou Tigermed Consulting

Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data managem...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 9,701
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3347

Financial Performance

In 2023, Hangzhou Tigermed Consulting's revenue was 7.38 billion, an increase of 4.21% compared to the previous year's 7.09 billion. Earnings were 2.02 billion, an increase of 0.91%.

Financial numbers in CNY